Vertex Pharmaceuticals’ (VRTX) “Market Perform” Rating Reiterated at Leerink Partners
Leerink Partners restated their market perform rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a research report sent to investors on Tuesday, MarketBeat Ratings reports. Leerink Partners currently has a $503.00 price objective on the pharmaceutical company’s stock, down from their previous price objective of $550.00. Several other equities analysts have also […]
Leerink Partners restated their market perform rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a research report sent to investors on Tuesday, MarketBeat Ratings reports. Leerink Partners currently has a $503.00 price objective on the pharmaceutical company’s stock, down from their previous price objective of $550.00. Several other equities analysts have also […]
